Panion has made an agreement with Copenhagen University about transfer and use of technical data from a study in dogs. The study is conducted by well-reputed researchers and is very relevant for Panion’s development of our gene therapy product for dogs with epilepsy. The study is not yet published by the researchers, but Panion may use the data in the contact with FDA and other authorities to speed up the development process from the day the agreement is signed.

“We are very pleased with the agreement, and we expect that this will ease our way to the next trial for our innovative product and to the market” says Anja Holm, CEO of Panion Animal Health.

Download >>